OrPro Therapeutics' Grant

OrPro Therapeutics raised a round of funding on July 31, 2012. Investors include National Heart Lung and Blood Institute.

OrPro Therapeutics is a pre-clinical stage biopharmaceutical company developing a class of safe, well-tolerated and effective inhaled non-systemic drugs based on the thioredoxin active site for the tr…

Articles about OrPro Therapeutics' Grant: